[Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study].
6-month multicentre, observational, open study evaluated the efficacy and tolerability of the new generation antipsychotic drug amisulpride in patients with acute schizophrenia. 99 patients were included in the study, 72 (72%) completed the 6-month observation. Marked improvement in CGI after 6 months of treatment was observed in 56 (56%) patients. Therapy with amisulpride reduced both positive (20% reduction of positive symptoms in the PANSS positive subscale in 78%) and negative symptoms (20% reduction of negative symptoms in the PANSS negative subscale in 77%). Amisulpride was well tolerated, adverse events responsible for premature withdrawal from the study were observed only in 6% patients.